Todd Hornsby - Apyx Medical Executive Vice President
| APYX Stock | USD 1.45 0.01 0.69% |
President
Mr. Todd Hornsby is the Executive Vice President of the Company. Mr. Hornsby joined Apyx Medical in August, 2014, and held the position of Vice President and General Manager of Advanced Energy prior to his promotion. Throughout his career, Todd has held various leadership positions and has extensive experience in sales, sales management, and with building strong teams and launching new technologies. Since joining Apyx Medical, Todd has focused primarily on the commercialization of Apyxs JPlasma advanced energy system. Prior to joining Apyx, Todd held roles of increasing seniority and responsibility at CryoLife, Inc. During his tenure, Todd directed the US Sales team, with a diversified product portfolio of biological heart valves and vascular grafts, surgical adhesives and hemostatic agents, dialysis access and CHF chronic heart failure products. Mr. Todd also directed successful integrations of three acquisitions into the US sales channel. Early in his medical device career, Todd held positions with Ethicon Endo Surgery and Medex Medical since 2019.
| Age | 47 |
| Tenure | 5 years |
| Address | 5115 Ulmerton Road, Clearwater, FL, United States, 33760-4004 |
| Phone | 727 384 2323 |
| Web | https://apyxmedical.com |
Todd Hornsby Latest Insider Activity
Tracking and analyzing the buying and selling activities of Todd Hornsby against Apyx Medical stock is an integral part of due diligence when investing in Apyx Medical. Todd Hornsby insider activity provides valuable insight into whether Apyx Medical is net buyers or sellers over its current business cycle. Note, Apyx Medical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Apyx Medical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Todd Hornsby over a month ago Acquisition by Todd Hornsby of 15000 shares of Apyx Medical at 1.77 subject to Rule 16b-3 |
Apyx Medical Management Efficiency
The company has return on total asset (ROA) of (0.2183) % which means that it has lost $0.2183 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1025) %, meaning that it created substantial loss on money invested by shareholders. Apyx Medical's management efficiency ratios could be used to measure how well Apyx Medical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.22 in 2024. Return On Capital Employed is likely to rise to -0.25 in 2024. At this time, Apyx Medical's Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 1.8 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 8.2 M in 2024.Similar Executives
| Found 2 records | PRESIDENT Age | ||
| Warren MD | Nutex Health | 52 | |
| Jonathan Arango | Mangoceuticals, Common Stock | 29 | |
Management Performance
| Return On Equity | -1.1 | ||||
| Return On Asset | -0.22 |
Apyx Medical Leadership Team
Elected by the shareholders, the Apyx Medical's board of directors comprises two types of representatives: Apyx Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Apyx. The board's role is to monitor Apyx Medical's management team and ensure that shareholders' interests are well served. Apyx Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Apyx Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles II, CEO President | ||
| Moshe Citronowicz, Senior Vice President | ||
| Tara Semb, Treasurer CFO | ||
| Todd Hornsby, Executive Vice President | ||
| Matthew CPA, Chief Officer | ||
| Stavros BCom, Executive Chairman |
Apyx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Apyx Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.1 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (0.58) % | ||||
| Operating Margin | (0.46) % | ||||
| Current Valuation | 65.04 M | ||||
| Shares Outstanding | 37.64 M | ||||
| Shares Owned By Insiders | 16.18 % | ||||
| Shares Owned By Institutions | 40.43 % | ||||
| Number Of Shares Shorted | 230.25 K | ||||
| Price To Earning | 4.04 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Apyx Stock Analysis
When running Apyx Medical's price analysis, check to measure Apyx Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apyx Medical is operating at the current time. Most of Apyx Medical's value examination focuses on studying past and present price action to predict the probability of Apyx Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apyx Medical's price. Additionally, you may evaluate how the addition of Apyx Medical to your portfolios can decrease your overall portfolio volatility.